A Randomized Placebo-Controlled Safety and Pharmacodynamic Study of KB002, a Chimeric Anti-GM-CSF Monoclonal Antibody, in Patients with Asthma
Néstor A. Molfino(Amgen (United States)), Geoffrey Yarranton, Philip G. Bardin(Monash Medical Centre), Philip J. Thompson, Alison Luckey(Global Antibiotic Research & Development Partnership)
Cited by 3
Related Papers
Control of Confounding and Reporting of Results in Causal Inference Studies. Guidance for Authors from Editors of Respiratory, Sleep, and Critical Care Journals
|Annals of the American Thoracic Society|2018|723
MEDI-563, a humanized anti–IL-5 receptor α mAb with enhanced antibody-dependent cell-mediated cytotoxicity function
|Journal of Allergy and Clinical Immunology|2010|578
Safety and pharmacokinetics of an anti-PcrV PEGylated monoclonal antibody fragment in mechanically ventilated patients colonized with Pseudomonas aeruginosa
|Critical Care Medicine|2012|182
Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study
|Journal of Antimicrobial Chemotherapy|2019|123